People and Business News — 9/22
People News
Clinovo appointed Nandish Poluru as Chief Executive.
Allucent, announced the appointment of Steffany Cox as its chief marketing officer.
Susan Robbins joined HeartcoR Solutions as its director of training. Additionally, Michelle Mills has joined the organization as director of ECG analysis and quality control.
MMS Holdings Inc. announced the appointment of Kelly J. Hill to Chief Strategy Officer.
Florence Healthcare has hired Kristin Surdam, who will lead the company’s thought leadership team and efforts to engage sponsors and contract research organizations, and Gunnar Esiason, who will lead patient-facing strategies.
Elligo Health Research announced Chief Scientific Officer Rebecca Kush, PhD, was recently elected Chair of the Vulcan Advisory Council.
Promontory Therapeutics Inc. announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls, and Kate Hogg Call as Vice President of Clinical Operations.
Parexel promoted Peyton Howell to the newly created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
Business News
Strata Oncology, Inc. announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH) trial.
Recognition
Jumo Health announced it has made Inc. Magazine’s Inc. 5000 list.
LaQuinta Jernigan, Chief Operating Officer for mdgroup, has been recognized as one of 100 most inspiring people in life sciences.
WCG’s Vice President, Patient Advocacy and Clinical Research Diversity, Lori Abrams, has been named a Diversity, Equity, and Inclusion Champion.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Phase III Trials Show Long-Term Efficacy of Cobenfy Treating Schizophrenia
November 1st 2024Cobenfy (xanomeline and trospium chloride) demonstrated sustained long-term efficacy, safety, and tolerability over 52 weeks in Phase III trials for adult schizophrenia patients, showing significant symptom improvement and quality of life benefits with minimal adverse effects.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
WCG Randomized 1,600 Participants for RSV Vaccine Trial
October 31st 2024A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
